Drug intelligence / Profile preview

human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells

Development stage: Unknown
Lead developer: Hospital-based stem cell therapy units
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intrathecal, Intramyocardial, Intracoronary

Overview

This is a combination cell therapy consisting of **human umbilical cord mesenchymal stem cells (UC-MSCs)** and **human cord blood mononuclear cells (UCB-MNCs)**. UC-MSCs are multipotent stem cells derived from the Wharton’s jelly of the umbilical cord that exhibit immunomodulatory and regenerative properties, such as anti-inflammatory effects, promotion of tissue repair, and regulation of immune responses[1][3][5]. UCB-MNCs are cells isolated from cord blood and include diverse cell types (e.g., lymphocytes, hematopoietic stem cells, progenitors) that can contribute to tissue regeneration, vascularization, and support the effect of stem cell therapies[4]. The combination aims to leverage the complementary mechanisms: UC-MSCs primarily modulate immunity and promote regeneration, while UCB-MNCs support microenvironmental revascularization and may enhance the therapeutic potential of MSCs[2]. This combination has been studied in chronic diseases, especially type 2 diabetes mellitus, cardiac indications (e.g., hypoplastic left heart syndrome), autoimmune diseases, and COVID-19[2][3][4][5][6][7]. The developer and manufacturer can vary by country and trial sponsor, typically academic medical centers or hospital-based cell therapy units.

Brand names: human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells
Other names: UC-MSC + UCB-MNChuman UC-MSC + human UCB-MNCumbilical cord mesenchymal stem cells + cord blood mononuclear cells

Beyond the preview

Go deeper on human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord mesenchymal stem cells + human cord blood mononuclear cells.

Explore the full profile